CRISPR Therapeutics Competitors, Revenue, Alternatives and Pricing

Claim your profile

Overview

Location:
Boston, MA USA
Total Funding:$218M
Industry:Biotech
Founded:2013
Lead Investor(s):Goldman Sachs & Co. LLC, Piper Jaffray & Co

City Ranking

Industry Ranking

State Ranking

Growjo 10k Ranking

Estimated Revenue & Financials

  • CRISPR Therapeutics's estimated annual revenue is currently $58.9M per year.
  • CRISPR Therapeutics received $113.8M in venture funding in January 2018.
  • CRISPR Therapeutics's estimated revenue per employee is $155,000
  • CRISPR Therapeutics's total funding is $218M.

Employee Data

  • CRISPR Therapeutics has 380 Employees.
  • CRISPR Therapeutics grew their employee count by 39% last year.
  • CRISPR Therapeutics currently has 48 job openings.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingPricing
Ultivue
$8.7M56-12%N/AN/A
Ohana Bioscienc...
$8.7M5660%N/AN/A
Compass Therape...
$16.4M10614%N/AN/A
Cell Signaling ...
$89.4M577N/AN/AN/A
Momenta Pharmac...
N/A220N/AN/AN/A
Emulate
$15.3M99-17%N/AN/A
ArQule
N/A94N/AN/AN/A
Hamilton Storag...
$17.2M1119%N/AN/A
Alnylam Pharmac...
$74.9M127731%N/AN/A
Transgenomic
N/A47N/AN/AN/A
Missing a competitor? Contribute!?
Submit

CRISPR Therapeutics is a leading gene-editing company focused on the development of transformative medicines using its proprietary CRISPR/Cas9 gene-editing platform. CRISPR/Cas9 is a revolutionary technology that allows for precise, directed changes to genomic DNA. Our multi-disciplinary team of world-class researchers and drug developers is working to translate this technology into breakthrough human therapeutics in a number of serious diseases. Our lead programs in beta-thalassemia and sickle cell disease have advanced to IND/CTA-enabling studies with a CTA filing planned by the end of 2017, and we are advancing additional programs in ex vivo and in vivo disease areas. In addition to our fully-owned programs, our strategic collaborations with Bayer AG and Vertex Pharmaceuticals expand our portfolio and enable us with unique capabilities. Through our private financings, partnerships, and IPO we have raised >$400M to fund and accelerate our portfolio. We have licensed the foundational CRISPR/Cas9 patent estate for human therapeutic use from our scientific founder, Dr. Emmanuelle Charpentier, who co-invented the application of CRISPR/Cas9 for gene editing. Our company is headquartered in Zug, Switzerland with R&D operations in Cambridge, Massachusetts, USA and some business operations in London, United Kingdom.

keywords:N/A

380

Number of Employees

$58.9M

Revenue (est)

48

Current Jobs

39%

Employee Growth %

$218M

Total Funding

N/A

Valuation

N/A

Accelerator

N/A

Type

Executive Contacts

NameTitleEmail
Christopher ErdmanVice President, Investor Relations & External AffairsEmail Available
Marc BeckerChief Financial OfficerEmail Available
Susan KimVice President, Investor RelationsEmail Available
Michael BruceSenior VP, Program Portfolio & Alliance ManagementEmail Available
Jonathan JonesVice President, New Business OpportunitiesEmail Available
Abhinav ShuklaVice President And Head, Manufacturing
Himanshu GargSr. Director, Enterprise Business Systems
James KasingerGeneral Counsel
Matthias WillVp Clinical Development
Demetrios KalaitzidisDirector, Immuno-Oncology

CRISPR Therapeutics News

09/03/2019 - BRIEF-Crispr Therapeutics AG May Offer And Sell From Time To Time Its Common Shares Having Aggregate Offering Price Of Up To $200 Million

BRIEF-Crispr Therapeutics AG May Offer And Sell From Time To Time Its Common Shares Having Aggregate Offering Price Of Up To $200 ...

09/08/2019 - Four U.S. CRISPR Trials Editing Human DNA to Research ...

A trial helmed by Massachusetts-based Vertex Pharmaceuticals and CRISPR Therapeutics is the first CRISPR-based clinical trial in the U.S. for ...

09/03/2019 - CRISPR Therapeutics inks $200M ATM stock sales deal

CRISPR Therapeutics (NASDAQ:CRSP) inks an agreement with Jefferies for the at-the-market sale of up to $200M of its common stock.

CRISPR Therapeutics Funding

DateAmountRoundLead InvestorsReference
2018-01-04$115.0MUndisclosedGoldman Sachs & Co. LLCArticle
2018-01-08$113.8MUndisclosedGoldman Sachs & Co. LLCArticle

CRISPR Therapeutics Executive Hires

DateNameTitleReference
2017-12-22Rodger NovakChairmanArticle